Novel myricetin derivatives: Design, synthesis and anticancer activity

Xue, Wei; Song, Baoan; Zhao, Hao; qi, Xing Bao; Huang, Yin Jiu; Liu, Xin Hua

doi:10.1016/j.ejmech.2015.04.063

Cited by 60 publications

(49 citation statements)

References 23 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those that have been undertaken have been concentrated on myricetin itself. Results from our previous investigations have highlighted that some myricetin derivatives have good biological activity in medicine and pesticides …”

Section: Introductionmentioning

confidence: 99%

Design, synthesis and antibacterial activities against Xanthomonas oryzae pv. oryzae, Xanthomonas axonopodis pv. Citri and Ralstonia solanacearum of novel myricetin derivatives containing sulfonamide moiety

Jiang¹,

Xu²,

Chen³

et al. 2019

Pest Management Science

Self Cite

View full text Add to dashboard Cite

BACKGROUND Myricetin and sulfonamide derivatives exhibited a wide variety of biological activity. In order to develop highly bioactive molecules, novel myricetin derivatives containing sulfonamide moiety were synthesized and antibacterial activities were investigated. RESULTS The results of bioassays indicated that compound A12, having an EC50 value of 4.7 μg mL−1, exhibited the best in vitro antibacterial activities against Xanthomonas oryzae pv. oryzae (X. oryzae pv. o.); EC50 values for this compound were even better than those of thiodiazole‐copper (TC, 71.4 μg mL−1) and bismerthiazol (BT, 54.7 μg mL−1). Compound A2, having an EC50 value of 1.1 μg mL−1, exhibited the best in vitro antibacterial activities against Xanthomonas axonopodis pv. citri (X. axonopodis pv. c); values were notably better than those of TC (60.0 μg mL−1) and BT (48.9 μg mL−1). Scanning electron microscopy analysis indicated that compounds A2 and A12 caused the cell membranes of X. axonopodis pv. c and X. oryzae pv. o. to break or deform, respectively. When the concentration of compound A12 was 100 μg mL−1, the effective curative activity against bacterial leaf blight of rice was 44.2% in vivo and the effective protection activity was 58.2% in vivo, results that were both better than values for TC (18.9 and 21.4%, respectively) and BT (12.5 and 12.5%, respectively). CONCLUSION Novel myricetin derivatives containing a sulfonamide moiety were synthesized and bioassay results showed that compounds A2 and A12 exhibited the best antibacterial activities. © 2019 Society of Chemical Industry

show abstract

Section: Introductionmentioning

confidence: 99%

Design, synthesis and antibacterial activities against Xanthomonas oryzae pv. oryzae, Xanthomonas axonopodis pv. Citri and Ralstonia solanacearum of novel myricetin derivatives containing sulfonamide moiety

Jiang¹,

Xu²,

Chen³

et al. 2019

Pest Management Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…The inhibitory concentrations of BIBR1532 are 93 nM in HeLa cells (2 h), 0.28 μM in MGC803 cells, and 0.17 μM in MDA‐MB‐231 cells for 24 hours . found that the small‐molecule inhibitor BIBR1532 induced G 1 arrest in the MCF‐7 cell line.…”

Section: Discussionmentioning

confidence: 96%

“…The inhibitory concentrations of BIBR1532 are 93 nM in HeLa cells (2 h), 0.28 μM in MGC803 cells, and 0.17 μM in MDA-MB-231 cells for 24 hours. [20][21][22] found that the small-molecule inhibitor BIBR1532 induced G 1 arrest in the MCF-7 cell line. They determined the IC 50 value of BIBR1532 as 10.4 μM at the 72nd hour in MCF-7 cell lines.…”

Section: Discussionmentioning

confidence: 99%

Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells

Doğan

Özateş

Bağca

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

It is emphasized that cancer stem cells (CSCs) forming the subpopulation of tumour cells are responsible for tumour growth, metastasis, and cancer drug resistance. Inadequate response to conventional therapy in breast cancer leads researchers to find new treatment methods and literature surveys that support CSC studies. A selective anticancer agent BIBR1532 inhibits the telomerase enzyme. Many of the chemotherapeutic drugs used in clinical trials have harmful effects, but the advantage of telomerase‐based inhibitors is that they are less toxic to healthy tissues. The phosphoinositide 3‐kinase (PI3K)/serine/threonine kinase (Akt)/mammalian target of rapamycin (mTOR) pathway is common in breast cancer, and the interaction between the mTOR pathway and human telomerase reverse transcriptase (hTERT) is essential for the survival of cancer cells. In our study, we treated MCF‐7, breast cancer stem cell (BCSC) and normal breast epithelial cell MCF10A with the BIBR1532 inhibitor. The IC 50 doses for the 48th hour of BIBR1532 treatment were detected as 34.59 μM in MCF‐7, 29.91 μM in BCSCs, and 29.07 μM in MCF10A. It has been observed that this agent induces apoptosis in the BCSC and MCF‐7 cell lines. According to the results of cell cycle analysis, G 2/M phase accumulation was observed in BCSC and MCF‐7 cell lines. It has also been shown that BIBR1532 suppresses telomerase activity in BCSC and MCF‐7. The effect of BIBR1532 on the mTOR signalling pathway has been investigated for the first time in this study. It is thought that the telomerase inhibitor may bring a new approach to the treatment and it may be useful in the treatment of CSCs.

show abstract

“…Different substitutions of chroman produce a large number of derivatives. Among them, 2‐phenylchroman‐4‐one derivatives ( 15 ‐ 18 ) are the most important ones . Because they are effective in inhibiting dyskerin, they are thought to inhibit the interaction of dyskerin and NOP10 and reduce telomerase activity .…”

Section: Small Molecule Inhibitorsmentioning

confidence: 99%

Therapeutic strategies for targeting telomerase in cancer

Chen

Tang

Shi

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Telomere and telomerase play important roles in abnormal cell proliferation, metastasis, stem cell maintenance, and immortalization in various cancers. Therefore, designing of drugs targeting telomerase and telomere is of great significance. Over the past two decades, considerable knowledge regarding telomere and telomerase has been accumulated, which provides theoretical support for the design of therapeutic strategies such as telomere elongation. Therefore, the development of telomere‐based therapies such as nucleoside analogs, non‐nucleoside small molecules, antisense technology, ribozymes, and dominant negative human telomerase reverse transcriptase are being prioritized for eradicating a majority of tumors. While the benefits of telomere‐based therapies are obvious, there is a need to address the limitations of various therapeutic strategies to improve the possibility of clinical applications. In this study, current knowledge of telomere and telomerase is discussed, and therapeutic strategies based on recent research are reviewed.

show abstract

Novel myricetin derivatives: Design, synthesis and anticancer activity

Cited by 60 publications

References 23 publications

Design, synthesis and antibacterial activities against Xanthomonas oryzae pv. oryzae, Xanthomonas axonopodis pv. Citri and Ralstonia solanacearum of novel myricetin derivatives containing sulfonamide moiety

Design, synthesis and antibacterial activities against Xanthomonas oryzae pv. oryzae, Xanthomonas axonopodis pv. Citri and Ralstonia solanacearum of novel myricetin derivatives containing sulfonamide moiety

Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells

Therapeutic strategies for targeting telomerase in cancer

Contact Info

Product

Resources

About